Orexo: Zubsolv Rx Data week 50

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.91% (5.97%), 4-week rolling average. The total number of Zubsolv tablets sold week 50 (49) reaching 344,314 (337,072). Zubsolv prescriptions (TRx) recorded a market share of 5.87% (5.98%), 4-week rolling average. Total number of prescriptions reaching 11,690 (11,865) during the week.

The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 7.4% (7.6%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.7% (6.6%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-01-17 Update
2017-01-16 Update
2017-01-16 Update
2017-01-13 Update
2017-01-10 Update
2017-01-10 Update
2017-01-09 Update
2017-01-09 Analys
2016-12-29 Update
2016-12-28 Update
2016-12-27 Update
2016-12-27 Update
2016-12-23 Update
2016-12-22 Update
2016-12-22 Update
2016-12-22 Update
2016-12-21 Update
2016-12-20 Update
2016-12-16 Update
2016-12-14 Update
2016-12-14 Update
2016-12-14 Update
2016-12-14 Analys
2016-12-12 Update
2016-12-12 Update